Dr Reddy’s hopes to finish Phase 3 trials of Covid-19 vaccine by March-May

By: |
October 28, 2020 10:26 PM

Dr Reddy's said that it needed to engage 100 and 1,400 volunteers for Phase 2 and 3 trials respectively.

Coronavirus, covid19, coronavirus news, coronavirus update, coronavirus vaccine, corona vaccine, Dr reddys, Sputnik, Russia, Russia vaccine, vaccine newsDr Reddy's has received approval from the Drug Control General of India (DCGI) for conducting human clinical trials of Sputnik V. (Reuters file photo)

Dr Reddy’s Laboratories on Wednesday said the Phase 3 trials of Russia’s Sputnik V vaccine for COVID-19 in India to be conducted by it are expected to be completed by the end of March depending on approvals and data validation. The city-headquartered drug maker, which has received approval from the Drug Control General of India (DCGI) for conducting human clinical trials of Sputnik V, was expected to complete the Phase 2 trials by December, Dr Reddy’s Chief Executive Officer Erez Israeli said.

“Phase-3, we should finish somewhere by March and then of course it depends on the ability to compile the data, obtain the approvals etc. It can be as early as end of March or April /May and beyond. It depends on the results. Its a combination of phase-2, global phase-3 and phase-3 in India,” he told reporters here after announcing the company’s Q2 results. He said the company needed to engage 100 and 1,400 volunteers for Phase 2 and 3 trials respectively. Dr Reddy’s and Russian Direct Investment Fund (RDIF), Russias sovereign wealth fund, entered into a partnership last month to conduct clinical trials of Sputnik V and its distribution in India. As part of the partnership, RDIF shall supply 100 million doses of the vaccine to Dr Reddy’s upon regulatory approval in India.

On August 11, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the worlds first registered vaccine against COVID-19 based on the human adenoviral vectors platform. Sputnik V is currently undergoing phase 3 clinical trials in Russia and the proposed number of subjects is 40,000.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1COVID-19: India says meeting Nepal’s vaccine requirement would be priority
2Delhi increased RT-PCR testing only after court’s prodding, many lives were lost: High Court
31,000 volunteers from Kolkata needed for COVID vaccine trial at NICED